Heart failure & cardiomyopathiesSecondary analysis
In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial
- Secondary analysis of the DELIVER randomised trial
Left ventricular ejection fraction (LVEF) changes extracted using a validated GPT-3.5 large language model
Authors' conclusion
Among patients hospitalized for HF in DELIVER, those with HFimpEF experienced a more adverse in-hospital clinical course, necessitating higher resource utilization beyond standard diuretic therapy compared with patients with HF and LVEF consistently >40%, but had similar in-hospital mortality. Treatment benefits of dapagliflozin were not modified by hospitalization type.
Study context
- Population
- Patients with heart failure (HF) and LVEF >40% randomised to dapagliflozin or placebo in DELIVER, with adjudicated HF hospitalizations
- Participants
- 6,263 patients
- Comparison
- HFimpEF vs LVEF consistently >40%
- HFimpEFn = 1,151
- Primary endpoint
- Complicated HF hospitalization (ICU stay, IV vasopressors/inotropes/vasodilators, invasive or non-invasive ventilation, mechanical fluid removal, ultrafiltration or mechanical circulatory support)
- Follow-up
- Median 2.3 years
Primary result
As reported in the abstract
P < 0.001
Further findings
LVEF reduction to ≤40% during HF hospitalization (subset with LVEF measurement)
P < 0.001
Length of stay and in-hospital mortality (first HF hospitalization)
- No significant difference between HFimpEF and LVEF consistently >40%
Dapagliflozin effect on total uncomplicated and complicated HF hospitalizations, by HFimpEF status
- Dapagliflozin reduced total uncomplicated and complicated HF hospitalizations irrespective of HFimpEF status
- P for interaction ≥ 0.30
- interaction P ≥0.30
Original publication
Summarised from the published abstract; every number is checked against it